JO
EPRX

John Overdeck’s Eupraxia Pharmaceuticals EPRX Stock Holding History

John Overdeck’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
221,084
+210,284
+1,947% +$1.45M ﹤0.01% 3296
2026
Q1 		$78.2K Buy
+10,800
New +$86.9K ﹤0.01% 4416

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

John Overdeck's EPRX Position: Q2 2026 in Review

John Overdeck increased its Eupraxia Pharmaceuticals (EPRX) stake by 1,947% in Q2 2026, buying an estimated $1.45M and bringing the position to 221,084 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3296.

John Overdeck first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • John Overdeck held 221,084 shares of Eupraxia Pharmaceuticals worth $1.46M as of Q2 2026.
  • John Overdeck bought 210,284 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.45M.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3296 holding.
  • John Overdeck first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.